Amarin Corporation plc (NASDAQ:AMRN) 42nd Annual J.P. Morgan Healthcare Conference January 10, 2024 4:30 PM ET Company Participants Pat Holt - President & CEO Conference Call Participants Jess Fye - JPMorgan Jess Fye Great. Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a Senior Biotech Analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Amarin. I'm joined up here by the company's President and CEO, Pat Holt. He's going to give a presentation on the busine ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...

-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Cash Flow of ~$10 Million -- -- 2024 Key Priorities Include Accelerating Revenue in Key European Launch Markets, Retaining IPE Market Leadership in the US and Maximizing Patient Uptake in Rest of World (RoW) Through Partnerships -- -- Company Announces Plan to Initiate Share Repurchase Program of Up to $50 Millio ...

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 8:00 AM ET Company Participants Jordan Zwick - SVP, Business Development & IR Patrick Holt - President & CEO Tom Reilly - CFO Conference Call Participants Louise Chen - Cantor Roanna Ruiz - Leerink Paul Choi - Goldman Sachs Operator Welcome to Amarin Corporation's conference call to discuss its third quarter 2023 financial results and business updates. I would now like to turn the conference call over to Jordan Zwick, Sen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Juris ...

Amarin Corporation plc (NASDAQ:AMRN) Cantor Fitzgerald Annual Global Healthcare Conference September 26, 2023 9:55 AM ET CompanyParticipants Patrick Holt - President and CEO Conference Call Participants Carvey Leung - Cantor Fitzgerald Carvey Leung My name is Carvey Leung, and I'm a research associate at Cantor here. Thank you for joining us today, Patrick. Question-and-Answer Session Q - Carvey Leung To start, can you tell us a little bit about yourself and your role at the company? Patrick Holt Yes, sure. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdicti ...

Summary of Amarin Corporation Conference Call Company Overview - **Company**: Amarin Corporation plc (NASDAQ: AMRN) - **Event**: Goldman Sachs 44th Annual Global Healthcare Conference - **Date**: June 12, 2023 - **Participants**: Aaron Berg (Interim President and CEO), Tom Reilly (CFO), Paul Choi (Goldman Sachs) Key Points Company Performance and Strategy - The management team acknowledges that the company is not where it wants to be, particularly regarding share price and overall value creation [4] - Focus is on the U.S. business, which has maintained a 60% market share since the entry of generics, generating over $1 billion since the product went generic [4][21] - The company aims to drive profitability while managing cash carefully, having saved over $100 million in expenses, which is 30% of their cash base [9] Market Dynamics - The U.S. market has seen a return to pre-COVID patient visit levels, which is a positive sign for business recovery [11] - Physicians continue to prescribe the brand over generics, indicating strong brand loyalty despite the presence of generics [15] - The company has maintained managed care access, with significant improvements in copay structures, making their product more accessible compared to generics [23] International Expansion - The company is focusing on expanding its presence in Europe, particularly in the UK and Nordic countries, where they have launched their product [5][31] - Recent partnerships in Canada, the Middle East, Australia, New Zealand, and China are expected to drive revenue growth in these regions [6][32] - The company is actively negotiating pricing and reimbursement in several European countries, including Spain, Italy, and France [8] Clinical Insights and Product Development - VASCEPA is recognized for its unique mechanism of action, which goes beyond just lowering triglycerides to reducing cardiovascular events [38] - The company is exploring a potential VASCEPA-statin combination, with ongoing discussions with regulatory bodies [41] Future Outlook - The management emphasizes the need to build value by focusing on high-risk patient populations and efficient operational structures [48] - The company is open to business development opportunities that can enhance valuation while prioritizing current operational needs [46] Challenges and Considerations - The company faces challenges in pricing negotiations and market entry in Europe, which require careful management of cash flow and strategic planning [8][34] - There is a recognition of the need for continued learning and adaptation in both U.S. and European markets to improve performance [48] Additional Insights - The management team is committed to leveraging their learnings from past experiences to enhance their market position and drive future growth [48] - The unique characteristics of the generic market in the U.S. complicate pricing strategies, making it difficult to generalize across different countries [34] This summary encapsulates the key discussions and strategic directions outlined during the conference call, highlighting Amarin's focus on maintaining market share, expanding internationally, and navigating the complexities of the healthcare landscape.

Amarin Corporation plc (NASDAQ:AMRN) Jefferies 2023 Global Healthcare Conference June 7, 2023 8:00 AM ET Company Participants Aaron Berg - Interim CEO & President Tom Reilly - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee All right. Good morning, everyone. Well, thank you for joining us on this morning session here to kick off the 2023 Jeffries Global Healthcare Conference. I'm Michael Yee, Managing Director and the Senior Biotech Analyst. Here with us to kick off a session is Amarin ...

Amarin Corporation plc (NASDAQ:AMRN) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Aaron Berg - Interim President & Chief Executive Officer Tom Reilly - Chief Financial Officer Steve Ketchum - President R&D and Chief Scientific Officer Conference Call Participants Louise Chen - Cantor Roanna Ruiz - SVB Securities Operator Greetings and welcome to Amarin Corporation's Conference Call to Discuss i ...